UNSPSC 51171858: Netupitant/Palonosetron

Netupitant/palonosetron is a fixed-dose combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.

UNSPSC 51171858 Netupitant/Palonosetron, a Commodity code, does not show relevant recent state and local procurement activity. The recent opportunities tagged to this code include a county office relocation notice, networking events, vendor forums, and survey feedback mechanisms — none of which involve purchase of this branded pharmaceutical combination. One exception is a Seminole County, Florida Invitation to Quote for Naloxone and Safe Drug Deactivation Systems (response due July 26, 2026), which targets opioid-response supplies rather than the chemotherapy antiemetic indicated by the code name. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026 with responses due March 26, 2026, solicits generic multi-source pharmaceuticals and OTC products through authorized wholesalers but does not mention Netupitant/Palonosetron specifically. The code appears to be used administratively by some issuing bodies but does not reflect actual state and local purchasing patterns in the available record.

No state or local government buyer has issued a solicitation for Netupitant/Palonosetron or similar branded antiemetics under this code in the recent-opportunities block. The Seminole County procurement targets emergency response pharmaceuticals, and the MMCAP cooperative focuses on generic multi-source drugs with volume pricing and wholesaler distribution. Netupitant/Palonosetron is a specialty oncology agent typically supplied through specialty pharmacy channels, hospital group purchasing organizations, and state Medicaid managed-care contracts rather than through standard state or local competitive procurement. Without evidence of current RFP, RFQ, or ITB activity for this specific product from county health departments, state pharmacy programs, or institutional buyers, the code does not warrant active pursuit at this time.